Avnish Deobhakta
Retina Specialist · Brooklyn, NYNPI 1356518674
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (40.8%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Alimera Sciences, Inc. at 42.3% of the total. Reporting peaked in 2019 at $23,498 and has fallen 95.5% since, to $1,062 in 2025. Among retina specialist clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 232 payments — averaging $197.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alimera Sciences, Inc.$19K
- Regeneron$8K
- Genentech USA, Inc.$7K
- AbbVie$5K
- Regeneron Healthcare Solutions, Inc.$2K
- Eyepoint US, Inc.$2K
- plus $2K from 13 others
What the payments were for
- Consulting fees$18,70341%
- Speaking & faculty fees$18,00039%
- Travel & lodging$2,5576%
- Food & beverage$6,46714%
- Education$770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alimera Sciences, Inc. | 27 | $19,373 |
| Regeneron | 8 | $8,317 |
| Genentech USA, Inc. | 13 | $7,458 |
| AbbVie(2 entities) | 26 | $4,862 |
| Regeneron Healthcare Solutions, Inc. | 79 | $2,120 |
| Eyepoint US, Inc. | 4 | $1,662 |
| Apellis Pharmaceuticals, Inc. | 25 | $597 |
| Bausch & Lomb Americas Inc. | 21 | $590 |
| Alcon | 10 | $385 |
| Amgen | 3 | $60 |
| Harrow Eye, LLC | 2 | $60 |
| Sun Pharmaceutical Industries Inc. | 2 | $48 |
| Tarsus Pharmaceuticals, Inc. | 2 | $47 |
| Aerie Pharmaceuticals, Inc. | 2 | $46 |
| Novartis | 2 | $43 |
| Oyster Point Pharma, Inc. | 2 | $42 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $40 |
| Mallinckrodt Hospital Products Inc. | 1 | $28 |
| Biotissue Holdings Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$45,803 in reported general payments places this provider in the 90th percentile of 99 retina specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EyleaAflibercept | 21 | $52,522 |
| RestasisCyclosporine | 35 | $31,870 |
| VabysmoFaricimab-Svoa | 11 | $24,091 |
| Restasis MultidoseCyclosporine | 14 | $8,656 |
| Bromfenac Sodium | 25 | $8,120 |
| CombiganBrimonidine Tartrate/Timolol | 17 | $7,923 |
| LumiganBimatoprost | 13 | $6,973 |
| ProlensaBromfenac Sodium | 18 | $5,819 |
| Prednisolone Acetate | 117 | $3,896 |
| Cyclosporine | 13 | $2,574 |
| Travoprost | 11 | $2,429 |
| Brimonidine Tartrate | 30 | $1,735 |
| Eplerenone | 22 | $1,446 |
| Ketorolac Tromethamine | 76 | $1,351 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 96 | $1,208 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Restasis Multidose, Combigan, Lumigan | $4,862 | $55,42379 claims |
| Regeneron Healthcare Solutions, Inc.Eylea | $2,120 | $52,52221 claims |
| Genentech USA, Inc.Vabysmo | $7,458 | $24,09111 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $40 | $5,81918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 99 retina specialist providers in New York.
Other retina specialist in Brooklyn
- Norman SaffraBrooklyn$5K
- Joseph PodhorzerBrooklyn$2K
- Mark HarooniBrooklyn$2K
- Paul HahnNanuet$238K
- Deepika MalikWoodbury$221K
- Szilard KissNew York$195K
- Ferhina AliValhalla$176K
- Donald D'amicoNew York$109K
- Matthew WitmerRochester$62K
- Edward HallRochester$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.